Text resize: A A A

milestones

2000 | 2001 | 2002 | 2003 | 2005| 2006| 2007| 2008| 2009

The proprietary chiral and biocatalysis technology at the Cambridge site and the scale up capability in the Mirfield site will add significant value to the company. These newer capabilities will add to our existing R&D and commercial infrastructure to position Dr. Reddy’s as a leading provider of Custom Pharmaceutical Services globally.

Satish Reddy Managing Director
and COO, Dr.Reddy's

Acquires Dowpharma’s small molecule business in UK

In April 2008, Dr. Reddy’s acquires a portion of Dowpharma Small Molecules business associated with its United Kingdom sites in Mirfield and Cambridge.

The research facility at Cambridge has proprietary chiral and biocatalysis technology and employs a team of 20 chemists of exceptional quality. Their highly specialized knowledge of Chemocatalysis and Biocatalysis has been creating immense value for innovator companies worldwide. The factory at Mirfield which manufactures intermediates and APIs, comprises of 45 people, is FDA, and UK MHRA approved and caters to customer in North America, Europe and Japan.

Click to read related memories

Acquires BASF’s Pharmaceutical contract manufacturing business and related facility at Shreveport, Louisiana, USA

Dr. Reddy’s acquires BASF’s pharmaceutical contract manufacturing business and related facility in Shreveport, Louisiana, USA. The 42-acre Shreveport facility manufactures and packages prescription and OTC pharmaceutical products, liquids, tablets and creams for the North American market. The acquisition enables Dr. Reddy’s to strengthen its supply chain for North America, provides a strong platform for pursuing additional growth opportunities and gives access to strong customer relationships with branded and generic companies. It will allow
Dr. Reddy’s to expand its portfolio of prescription generics, OTC capabilities and its ability to supply generic products to US government agencies.

Click to read related memories

Dr. Reddy’s formally announces its US Specialty Business, Promius™ Pharma, LLC

On 22^nd September 2008, Dr. Reddy’s formally announces its US Specialty Business, Promius^TM Pharma, LLC, a wholly-owned subsidiary of Dr. Reddy’s Laboratories located in Bridgewater, NJ.

Promius^TM Pharma will initially focus on the branded dermatology market in the US and is based on a platform of strategic licensing initiatives and internal product development activities.

Click to read related memories

2008

Aerial view of the API plant at Mirfield, UK